$BFYW
Better For You Wellness, Inc.

2022 Q4 Form 10-Q Financial Statement

#000121390022065323 Filed on October 21, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022 Q1
Revenue $6.986K $1.520K
YoY Change
Cost Of Revenue $5.823K $3.489K $730.00
YoY Change
Gross Profit $1.163K -$608.00 $790.00
YoY Change
Gross Profit Margin 16.65% 51.97%
Selling, General & Admin $258.4K $361.1K $546.9K
YoY Change -75.76% 2477.67%
% of Gross Profit 22218.49% 69226.58%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $190.00 $120.00
YoY Change
% of Gross Profit 16.34%
Operating Expenses $605.2K $707.5K $482.0K
YoY Change -43.24% 4949.79%
Operating Profit -$604.0K -$708.1K -$481.2K
YoY Change -43.34% 4955.93%
Interest Expense -$55.94K $61.04K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$55.94K -$79.02K
YoY Change
Pretax Income -$659.9K -$787.1K -$481.2K
YoY Change -38.1% 5518.2%
Income Tax
% Of Pretax Income
Net Earnings -$659.9K -$787.1K -$481.2K
YoY Change -38.1% 5518.17% 9650.56%
Net Earnings / Revenue -9446.55% -31657.24%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 -$2.116K -$1.448K
COMMON SHARES
Basic Shares Outstanding 390.0M shares 372.0M shares
Diluted Shares Outstanding 372.0M 372.0M

Balance Sheet

Concept 2022 Q4 2022 Q3 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.150K $2.750K $9.640K
YoY Change
Cash & Equivalents $3.154K $2.745K $9.719K
Short-Term Investments
Other Short-Term Assets $101.5K $106.3K
YoY Change
Inventory $1.657K $5.918K $13.11K
Prepaid Expenses $23.43K
Receivables $1.495K $123.00
Other Receivables $108.3K $107.1K
Total Short-Term Assets $216.1K $115.0K $9.640K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.741K $2.906K $730.00
YoY Change
Goodwill $583.5K $577.5K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $585.2K $580.4K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $216.1K $115.0K $9.640K
Total Long-Term Assets $585.2K $580.4K $0.00
Total Assets $801.3K $695.4K $9.640K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $311.5K $9.820K $345.4K
YoY Change
Accrued Expenses $0.00 $0.00 $172.9K
YoY Change -100.0% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $202.0K $863.8K $202.5K
YoY Change 28.86% 233356.76%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $799.5K $1.131M $375.4K
YoY Change 192.03% 19173.25%
LONG-TERM LIABILITIES
Long-Term Debt $601.5K $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $601.5K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $799.5K $1.131M $375.4K
Total Long-Term Liabilities $601.5K $0.00 $0.00
Total Liabilities $1.401M $1.131M $375.4K
YoY Change 411.73% 19173.3%
SHAREHOLDERS EQUITY
Retained Earnings -$3.958M -$3.295M -$1.748M
YoY Change 117.78% 3520.95%
Common Stock $39.00K $38.52K $37.08K
YoY Change 7.43% 6.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$599.6K -$436.0K -$365.8K
YoY Change
Total Liabilities & Shareholders Equity $801.3K $695.4K $9.640K
YoY Change

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022 Q1
OPERATING ACTIVITIES
Net Income -$659.9K -$787.1K -$481.2K
YoY Change -38.1% 5518.17% 9650.56%
Depreciation, Depletion And Amortization $190.00 $120.00
YoY Change
Cash From Operating Activities -$126.0K -$278.3K -$144.3K
YoY Change -19.45% 8183.63%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$2.300K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$2.320K
YoY Change
Cash From Investing Activities $0.00 -$2.300K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $68.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 127.0K 280.7K 154.0K
YoY Change -18.79% 8253.87%
NET CHANGE
Cash From Operating Activities -126.0K -278.3K -144.3K
Cash From Investing Activities 0.000 -2.300K
Cash From Financing Activities 127.0K 280.7K 154.0K
Net Change In Cash 1.030K 60.00 9.640K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$126.0K -$278.3K -$144.3K
Capital Expenditures $0.00 -$2.300K
Free Cash Flow -$126.0K -$276.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
53 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1131343 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-08-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56262
dei Entity Registrant Name
EntityRegistrantName
Better For You Wellness, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2903933
dei Entity Address Address Line1
EntityAddressAddressLine1
1349 East Broad Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Columbus
dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
43205
dei City Area Code
CityAreaCode
(614)
dei Local Phone Number
LocalPhoneNumber
368-9898
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
389995988 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2745 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9719 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
5918 usd
CY2022Q1 us-gaap Inventory Net
InventoryNet
13106 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
106333 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
114996 usd
CY2022Q1 us-gaap Assets Current
AssetsCurrent
22825 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2906 usd
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
731 usd
CY2022Q3 us-gaap Goodwill
Goodwill
577473 usd
CY2022Q3 us-gaap Assets
Assets
695375 usd
CY2022Q1 us-gaap Assets
Assets
23556 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
342193 usd
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
305666 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
521593 usd
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5385 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9824 usd
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
184083 usd
CY2022Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
257680 usd
CY2022Q1 us-gaap Liabilities
Liabilities
495134 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
700000 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
700000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
700000 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
700000 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
70 usd
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
70 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
385198451 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
385198451 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
380108169 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
380108169 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
38520 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
37075 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2820220 usd
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1485364 usd
CY2022Q1 bfyw Shares Cancelable
SharesCancelable
-250000 usd
CY2022Q1 us-gaap Minority Interest
MinorityInterest
4358 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3294778 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1748445 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-435968 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-471578 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
695375 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23556 usd
CY2022Q3 bfyw Merchandise Sales Amount
MerchandiseSalesAmount
2881 usd
bfyw Merchandise Sales Amount
MerchandiseSalesAmount
15968 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
3489 usd
us-gaap Cost Of Revenue
CostOfRevenue
13757 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
-608 usd
us-gaap Gross Profit
GrossProfit
2211 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
346344 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
7000 usd
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
862751 usd
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
77000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
361131 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7005 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
601707 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9057 usd
us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
707475 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
14005 usd
us-gaap Operating Expenses
OperatingExpenses
1464458 usd
us-gaap Operating Expenses
OperatingExpenses
86057 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-708083 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14005 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1462247 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-86057 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
61043 usd
us-gaap Interest Expense
InterestExpense
97409 usd
CY2022Q3 us-gaap Other Expenses
OtherExpenses
17980 usd
us-gaap Other Expenses
OtherExpenses
23043 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-79023 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-120452 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-787106 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14005 usd
us-gaap Net Income Loss
NetIncomeLoss
-1582699 usd
us-gaap Net Income Loss
NetIncomeLoss
-86057 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
372031446 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
360000680 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
372031446 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
250434405 shares
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-471578 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
254250 usd
CY2022Q2 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
577473 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
262157 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
78471 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-4358 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-759227 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-62812 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
250998 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3753 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
315346 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
63853 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-220000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-787106 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-435968 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-55965 usd
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
70000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
3951 usd
CY2021Q2 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
20768 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-81477 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-42723 usd
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
7000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
2990 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-14005 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-46738 usd
us-gaap Net Income Loss
NetIncomeLoss
-1582699 usd
us-gaap Net Income Loss
NetIncomeLoss
-86057 usd
bfyw Common Stock Issued
CommonStockIssued
7000 usd
bfyw Preferred Stocks Issued
PreferredStocksIssued
70000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
505248 usd
bfyw Stock Option Plan Expenses
StockOptionPlanExpenses
357503 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
61043 usd
us-gaap Depreciation
Depreciation
124 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-7188 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
114914 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-174259 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1750 usd
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
257680 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
53 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-683033 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7307 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2299 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2299 usd
us-gaap Stock Issued1
StockIssued1
56640 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3750 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
3750 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
620000 usd
bfyw Expenses Contributed To Capital
ExpensesContributedToCapital
78471 usd
bfyw Expenses Contributed To Capital
ExpensesContributedToCapital
6942 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
36527 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
365 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
678358 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7307 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6974 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9719 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2745 usd
CY2022Q2 bfyw Fair Market Value
FairMarketValue
550000 usd
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
700000 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
700000 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
700000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Other Cash Equivalents At Carrying Value
OtherCashEquivalentsAtCarryingValue
2745 usd
CY2022Q1 us-gaap Other Cash Equivalents At Carrying Value
OtherCashEquivalentsAtCarryingValue
9642 usd
us-gaap Other General Expense
OtherGeneralExpense
78471 usd
CY2022Q3 bfyw Deferred Compensations Equity
DeferredCompensationsEquity
267504 usd
CY2022Q2 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock.
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
346334 usd
CY2021Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
7000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
862751 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
77000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
385198451 shares
CY2022Q3 us-gaap Capital Units Outstanding
CapitalUnitsOutstanding
78.32 shares
us-gaap Income Loss From Subsidiaries Net Of Tax
IncomeLossFromSubsidiariesNetOfTax
4136814 usd
CY2022Q3 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
868731 usd
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q2 bfyw Investment Owned Subject To Option Prices
InvestmentOwnedSubjectToOptionPrices
5000000 usd
CY2022Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2022Q2 bfyw Purchase Price Per Share Equal To Percentage
PurchasePricePerShareEqualToPercentage
0.90 pure
CY2022Q2 bfyw Stock Issued During Period Shares Common Stock Purchase Warrant For Purchase
StockIssuedDuringPeriodSharesCommonStockPurchaseWarrantForPurchase
1785714 shares
us-gaap Salaries And Wages
SalariesAndWages
65000 usd
bfyw Consulting Agreement Description
ConsultingAgreementDescription
Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month.
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
31000 usd
CY2022Q2 us-gaap Short Term Debt Interest Rate Increase
ShortTermDebtInterestRateIncrease
0.12 pure
CY2022Q2 us-gaap Investment Maturity Date
InvestmentMaturityDate
2023-06-07
CY2022Q2 bfyw Common Stock Conversion Price Per Share
CommonStockConversionPricePerShare
0.037
CY2022Q2 us-gaap Securities Purchased Under Agreements To Resell Increase
SecuritiesPurchasedUnderAgreementsToResellIncrease
22320 usd
CY2022Q2 srt Financing Receivable Nonaccrual To Outstanding Percent
FinancingReceivableNonaccrualToOutstandingPercent
0.08 pure
CY2022Q2 us-gaap Public Utilities Approved Rate Increase Decrease Percentage
PublicUtilitiesApprovedRateIncreaseDecreasePercentage
1.20 pure
CY2022Q2 us-gaap Standby Bond Purchase Commitment Expiration Period
StandbyBondPurchaseCommitmentExpirationPeriod
P5Y
CY2022Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
22320 usd
bfyw Noncancelable Warrants Percentage
NoncancelableWarrantsPercentage
0.08 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.20 pure
CY2022Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
700000 shares
CY2022Q3 bfyw Share Based Compensation Arrangement By Share Based Payment Award Options Forfeituresdescription
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresdescription
On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00. 
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
20000000 shares
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
2500000 shares
bfyw Stock Option Description
StockOptionDescription
17,500,000 shares vest over the next 2 years, 2,500,000 shares per quarter.
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
25
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
2127565
CY2022Q3 us-gaap Share Price
SharePrice
15
CY2022Q1 us-gaap Share Price
SharePrice
11
bfyw Stock Option Exercise
StockOptionExercise
209725
bfyw Total Unamortized Stock Option Expense
TotalUnamortizedStockOptionExpense
2000920 usd
bfyw Total Payments Considered Contributions
TotalPaymentsConsideredContributions
413441 usd
CY2022Q3 us-gaap Alternative Investment
AlternativeInvestment
250492 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
usd
us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
3750 usd
bfyw Stock Option Expanses
StockOptionExpanses
315346 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
63853 usd
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
220000 usd
CY2022Q3 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
190320 usd
CY2022Q3 us-gaap Due From Officers Or Stockholders Current
DueFromOfficersOrStockholdersCurrent
2489 usd
CY2022Q4 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
17500 usd
CY2022Q4 bfyw Loan Amount
LoanAmount
35000 usd
bfyw Balance Agreed Paid
BalanceAgreedPaid
17500 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
usd
CY2022Q1 us-gaap Goodwill
Goodwill
usd
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
usd
CY2022Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
usd
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
usd
CY2022Q3 bfyw Shares Cancelable
SharesCancelable
usd
CY2022Q3 us-gaap Minority Interest
MinorityInterest
usd
CY2022Q3 us-gaap Revenues
Revenues
usd
CY2021Q3 us-gaap Revenues
Revenues
usd
CY2021Q3 bfyw Merchandise Sales Amount
MerchandiseSalesAmount
usd
bfyw Merchandise Sales Amount
MerchandiseSalesAmount
usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
usd
us-gaap Gross Profit
GrossProfit
usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2021Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
usd
us-gaap Interest Expense
InterestExpense
usd
CY2021Q3 us-gaap Other Expenses
OtherExpenses
usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2022Q2 bfyw Stock Issued During Period Value Common Shares Canceled And Returned To The Company
StockIssuedDuringPeriodValueCommonSharesCanceledAndReturnedToTheCompany
usd
CY2022Q2 bfyw Stock Issued During Period Value Common Shares Issued For Shares Payable
StockIssuedDuringPeriodValueCommonSharesIssuedForSharesPayable
usd
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
usd
bfyw Common Stock Issued
CommonStockIssued
usd
bfyw Preferred Stocks Issued
PreferredStocksIssued
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
bfyw Stock Option Plan Expenses
StockOptionPlanExpenses
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
usd
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
usd
us-gaap Stock Issued1
StockIssued1
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
bfyw Proceeds From Restricted Common Stock
ProceedsFromRestrictedCommonStock
375.13 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001852707

Files In Submission

Name View Source Status
0001213900-22-065323-index-headers.html Edgar Link pending
0001213900-22-065323-index.html Edgar Link pending
0001213900-22-065323.txt Edgar Link pending
0001213900-22-065323-xbrl.zip Edgar Link pending
bfyw-20220831.xsd Edgar Link pending
f10q0822ex31_better.htm Edgar Link pending
f10q0822ex32_better.htm Edgar Link pending
f10q0822_betterforyou.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bfyw-20220831_def.xml Edgar Link unprocessable
bfyw-20220831_lab.xml Edgar Link unprocessable
bfyw-20220831_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bfyw-20220831_pre.xml Edgar Link unprocessable
f10q0822_betterforyou_htm.xml Edgar Link completed